Verzenio® + Fulvestrant | Efficacy | Verzenio (abemaciclib)
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1 | SpringerLink
PDF) MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
IJMS | Free Full-Text | Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
![PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1b316b998a6f3d4685942edb98b16960acc9a40c/4-Figure2-1.png "PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar")
PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
Verzenios, INN - abemaciclib
Kaplan–Meier curve for overall survival in the premenopausal population... | Download Scientific Diagram
Verzenios, INN-abemaciclib
Proffered Paper session: Breast cancer, metastatic LBA15 - MONARCH 3: Interim overall survival (OS) results of abemaciclib plus
MONARCH 3: Overall Survival Results of Abemaciclib Plus Nonsteroidal AI for HR+/HER2− Advanced Breast Cancer | PracticeUpdate
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
Subgroup analysis of progression-free survival. ECOG PS, Eastern... | Download Scientific Diagram
MONARCH 3: OS Update - Slideset Download - ESMO Congress Paris | CCO
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer | Future Oncology
Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis | Eli Lilly and Company
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Verzenio® + Fulvestrant | Efficacy | Verzenio (abemaciclib)
Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer
